Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.45 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.44 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.43 |
| ▸ | JAK2 | O60674 | 1/20 | 0.42 |
| ▸ | JAK1 | P23458 | 1/20 | 0.42 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4314786 | 0.93 | RECQL (0.52) | USP30RECQLUSP2SMN1; SMN2HSD11B1 | |
| SCHEMBL2674708 | 0.92 | RECQL (0.53) | USP30RECQLUSP2SMN1; SMN2GPR119 | |
| SCHEMBL2673967 | 0.86 | RECQL (0.59) | USP30RECQLUSP2SMN1; SMN2GPR119 | |
| SCHEMBL1624007 | 0.86 | USP30 (0.46) | USP30RECQLUSP2SMN1; SMN2HSD11B1 | |
| SCHEMBL20521571 | 0.86 | USP30 (0.54) | USP30RECQLHSD11B1DDB1CRBN | |
| SCHEMBL34473785 | 0.85 | USP30 (0.53) | USP30RECQLHSD11B1DDB1CRBN | |
| SCHEMBL2675028 | 0.83 | RECQL (0.52) | USP30RECQLUSP2SMN1; SMN2GPR119 | |
| SCHEMBL25081632 | 0.82 | USP2 (0.58) | USP30RECQLUSP2SMN1; SMN2HSD11B1 | |
| SCHEMBL641644 | 0.82 | USP30 (0.51) | USP30RECQLHSD11B1DDB1CRBN | |
| SCHEMBL31209979 | 0.82 | USP30 (0.51) | USP30RECQLHSD11B1DDB1CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240368193-A1 | KRAS INHIBITORS | ELI LILLY AND COMPANY | 2024-11-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240368193-A1 | KRAS INHIBITORS | KRAS, NRAS, HRAS | USP30 2132/4885RECQL 210/4885USP2 3256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.